Deck 20: Assessment of the Transgender or Gender Diverse Adult

Question 1

Which of the following is true concerning gender-affirming treatments?

A) All transgender patients elect gender-affirming treatments.
B) Trans males are more likely to use pharmacological treatments over nonpharmacological treatments.
C) Gender-affirming treatments are reserved for those preparing for transition surgery.
D) Not all individuals undergo gender-affirming treatments.

Answer 1

Not all individuals undergo gender-affirming treatments.

Question 2

For both trans women and trans men receiving gender-affirming treatments, labs should be monitored at regular intervals. The recommendation for follow-up intervals is:

A) Every 3 months for the first year, then once or twice annually
B) Every month for the first year, then every 3 months after that
C) Every 6 months for the first year, then annually
D) Regular labs should be checked annually

Answer 2

Every 3 months for the first year, then once or twice annually

Question 3

Gender-neutral pronouns are often used to avoid assuming the binary gender classifications denoted by pronouns such as he and she. Which of the following is not a gender-neutral pronoun?

A) Ze
B) Hir
C) They
D) Person

Answer 3

Person

Question 4

Which of the following is true of trans men?

A) Contraception is no longer needed.
B) A quarterly lab to monitor hormonal treatment is recommended for life.
C) There is an increased risk of polycystic ovarian syndrome.
D) There is an increased risk of migraine headaches.

Question 5

Which of the following is not a potential side effect/risk with exogenous testosterone therapy?

A) Elevated liver enzymes
B) Hyperlipidemia
C) Diabetes
D) Peptic ulcer disease

Question 6

While seeing a trans-male patient with an acute complaint, you should not:

A) Obtain demographic information, including what the patient chooses to be called
B) Complete a focused medical history specific to the complaint
C) Document all prior gender reassignment procedures
D) Document all current medications

Question 7

Your transgender patient has had a gonadectomy and is no longer on hormone replacement. You should screen for:

A) Free testosterone
B) Deep venous thrombosis
C) Bone density
D) All of the above

Question 8

The term transgender is used to describe all of the following except:

A) Individuals whose gender identity varies from the gender assigned at birth
B) Individuals who fluidly identify as neither male nor female
C) Individuals classified by sexual orientation
D) Approximately 1 million individuals in the United States

Question 9

Hormonal therapies for trans women carry increased risks for:

A) Electrolyte abnormalities
B) Weight gain
C) Deep vein thrombosis
D) All of the above

Question 10

Contraindications for testosterone therapy in trans men include:

A) Anemia
B) Pregnancy
C) Gallbladder disease
D) History of deep venous thrombosis

Question 11

For trans men on hormone therapy, labs to assess treatment response should include a complete blood count (CBC). For what, specifically, is it important to monitor the CBC?

A) Anemia
B) Thrombocytopenia
C) Polycythemia
D) Neutropenia

Question 12

Every effort should be made to treat other medical conditions prior to beginning gender-affirming treatments. Which of the following would be imperative to address/treat prior to beginning treatments?

A) Cardiovascular disease
B) Depression/mood disorders
C) Urological conditions
D) Sleep disturbances

Question 13

Among trans women, the risk for deep venous thrombosis is higher if:

A) They use oral estrogen replacement
B) They use cutaneous estrogen replacement
C) They take spironolactone
D) They use goserelin as a GnRH agonist